Literature DB >> 8710069

Follow-up study of risk factors in progressive supranuclear palsy.

L I Golbe1, R S Rubin, R P Cody, J M Belsh, R C Duvoisin, C Grosmann, F E Lepore, M H Mark, R C Sachdeo, J I Sage, T R Zimmerman.   

Abstract

The cause of progressive supranuclear palsy (PSP) is not known and has been little studied. The one previous controlled epidemiologic survey, performed at our center in 1986, found small-town experience and greater educational attainment as PSP risks, but, in retrospect, these results may have been produced by ascertainment bias. Since that time, several anecdotal reports have implicated heredity and various environmental exposures in the cause of some cases of PSP. To clarify the results of the previous study and to evaluate the more recently implicated candidate factors in a controlled fashion, we mailed a validated 69-item questionnaire to 91 personally examined patients with PSP and 104 unmatched controls with other neurologic conditions for which they had been referred to our tertiary neurologic center. We were able to match 75 subjects from each group by year of birth, sex, and race and subjected them to a separate matched-pair analysis. We allowed surrogates to supply any or all of the responses. Questions concerned hydrocarbon, pesticide, and herbicide exposure; urban/rural living; auto repair and other occupations; head trauma; educational attainment; maternal age; and family history of PSP, parkinsonism, dementia, and other neurologic conditions. A statistically significant finding was that patients with PSP were less likely to have completed at least 12 years of school (matched odds ratio = 0.35, 95% CI = 0.12-0.95, p = 0.022; unmatched odds ratio = 0.44, 95% CI = 0.21-0.89, p = 0.020). We hypothesize that this result may be a proxy for poor early-life nutrition or for occupational or residential exposure to an as-yet unsuspected toxin. Future studies should examine these potential risk factors in PSP.

Entities:  

Mesh:

Year:  1996        PMID: 8710069     DOI: 10.1212/wnl.47.1.148

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  14 in total

Review 1.  Progressive supranuclear palsy.

Authors:  H U Rehman
Journal:  Postgrad Med J       Date:  2000-06       Impact factor: 2.401

Review 2.  Progressive supranuclear palsy (Steele-Richardson-Olszewski disease).

Authors:  H R Morris; N W Wood; A J Lees
Journal:  Postgrad Med J       Date:  1999-10       Impact factor: 2.401

Review 3.  Progressive supranuclear palsy: clinical features, pathophysiology and management.

Authors:  A Rajput; A H Rajput
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

4.  Current and future treatments in progressive supranuclear palsy.

Authors:  Irene van Balken; Irene Litvan
Journal:  Curr Treat Options Neurol       Date:  2006-05       Impact factor: 3.598

5.  A geographical cluster of progressive supranuclear palsy in northern France.

Authors:  Dominique Caparros-Lefebvre; Lawrence I Golbe; Vincent Deramecourt; Claude-Alain Maurage; Vincent Huin; Valerie Buée-Scherrer; Helene Obriot; Bernard Sablonnière; Francois Caparros; Luc Buée; Andrew J Lees
Journal:  Neurology       Date:  2015-09-09       Impact factor: 9.910

6.  Environmental and occupational risk factors for progressive supranuclear palsy: Case-control study.

Authors:  Irene Litvan; Peter S J Lees; Christopher R Cunningham; Shesh N Rai; Alexander C Cambon; David G Standaert; Connie Marras; Jorge Juncos; David Riley; Stephen Reich; Deborah Hall; Benzi Kluger; Yvette Bordelon; David R Shprecher
Journal:  Mov Disord       Date:  2016-02-08       Impact factor: 10.338

7.  Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy.

Authors:  Günter U Höglinger; Nadine M Melhem; Dennis W Dickson; Patrick M A Sleiman; Li-San Wang; Lambertus Klei; Rosa Rademakers; Rohan de Silva; Irene Litvan; David E Riley; John C van Swieten; Peter Heutink; Zbigniew K Wszolek; Ryan J Uitti; Jana Vandrovcova; Howard I Hurtig; Rachel G Gross; Walter Maetzler; Stefano Goldwurm; Eduardo Tolosa; Barbara Borroni; Pau Pastor; Laura B Cantwell; Mi Ryung Han; Allissa Dillman; Marcel P van der Brug; J Raphael Gibbs; Mark R Cookson; Dena G Hernandez; Andrew B Singleton; Matthew J Farrer; Chang-En Yu; Lawrence I Golbe; Tamas Revesz; John Hardy; Andrew J Lees; Bernie Devlin; Hakon Hakonarson; Ulrich Müller; Gerard D Schellenberg
Journal:  Nat Genet       Date:  2011-06-19       Impact factor: 38.330

8.  Clinical, cognitive, and behavioural correlates of white matter damage in progressive supranuclear palsy.

Authors:  Federica Agosta; Sebastiano Galantucci; Marina Svetel; Milica Ječmenica Lukić; Massimiliano Copetti; Kristina Davidovic; Aleksandra Tomić; Edoardo G Spinelli; Vladimir S Kostić; Massimo Filippi
Journal:  J Neurol       Date:  2014-03-06       Impact factor: 4.849

Review 9.  Neurodegenerative diseases: an overview of environmental risk factors.

Authors:  Rebecca C Brown; Alan H Lockwood; Babasaheb R Sonawane
Journal:  Environ Health Perspect       Date:  2005-09       Impact factor: 9.031

10.  Concomitant progressive supranuclear palsy and chronic traumatic encephalopathy in a boxer.

Authors:  Helen Ling; Eleanna Kara; Tamas Revesz; Andrew J Lees; Gordon T Plant; Davide Martino; Henry Houlden; John Hardy; Janice L Holton
Journal:  Acta Neuropathol Commun       Date:  2014-02-21       Impact factor: 7.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.